In aesthetic medicine, treating severe dermal atrophy, deep crepey skin, and compromised tissue repair presents a unique challenge. Traditional crosslinked hyaluronic acid (HA) fillers excel at replacing lost volume, but placing volumetric gels into thin, structurally depleted skin can result in over-projection, surface unnaturalness, or the Tyndall effect.<\/p>\n\n\n\n
Rather than merely expanding tissue space with volumetric fillers, regenerative aesthetic medicine focuses on physiological bioremodeling<\/strong>\u2014reprogramming the extracellular matrix (ECM) to heal and re-densify itself from within.<\/p>\n\n\n\n Leading this shift toward true cellular regeneration are Polynucleotides (PN)<\/strong> and Polydeoxyribonucleotides (PDRN)<\/strong>. Derived from purified salmon DNA fragments, these biopolymers act as direct physiological signals that bind adenosine A2A cell-surface receptors, triggering native collagen synthesis, wound repair, and long-term tissue restoration, and are actively being invested in by preimum biotech organizations like Ninaveli<\/a>, Allergan Aesthetics, and Medytox.<\/p>\n\n\n\n Dermal atrophy occurs when the rate of extracellular matrix breakdown outpaces the synthetic capacity of local fibroblasts. Driven by intrinsic aging, chronic UV exposure, and hormonal shifts:<\/p>\n\n\n\n Simply hydrating this depleted environment with non-crosslinked HA provides temporary moisture, but it fails to provide the biological signals needed to rebuild damaged dermal architecture.<\/p>\n\n\n\n Polynucleotides are high-molecular-weight DNA polymers composed of purine and pyrimidine nucleotide chains. When introduced into the dermis via intradermal micro-injections or transdermal micro-channeling, they operate through two distinct pathways:<\/p>\n\n\n\n The primary therapeutic driver of PN\/PDRN is its ability to selectively bind to adenosine A2A cell-surface receptors<\/strong> on dermal fibroblasts, endothelial cells, and immune cells:<\/p>\n\n\n\n As endonucleases gradually cleave the long DNA polymers of PN\/PDRN into smaller nucleosides and nucleotides, these free bases are reabsorbed by local cells via the purine salvage pathway<\/strong>. This provides ready-made building blocks for cellular DNA repair and synthesis, saving metabolic energy during tissue recovery.<\/p>\n\n\n\n Simultaneously, the polymeric structure of PN binds large amounts of water molecules, providing immediate viscoelastic hydration and isometric cushioning to thin, creping skin.<\/p>\n\n\n\n In a comprehensive pharmacological study published in Pharmaceuticals (MDPI)<\/em>, “PDRN: A Bio-Rejuvenating Agent for Tissue Repair and Regeneration,”<\/strong> researchers evaluated the molecular pathways driven by polydeoxyribonucleotides.<\/p>\n\n\n\n The objective data confirmed that PDRN specifically binds A2A receptors, triggering a statistically significant upregulation of collagen Type I deposition, VEGF expression, and capillary neovascularization<\/strong> in damaged dermal models. The researchers noted that blocking the A2A receptor completely eliminated PDRN’s regenerative effects, proving its receptor-mediated mechanism.<\/p>\n\n\n\n In a clinical evaluation published in PMC<\/em>, “Polynucleotides in Aesthetic Medicine: A Systematic Review of Clinical Efficacy,”<\/strong> investigators tracked subjects receiving intradermal PN\/PDRN injections for facial atrophy and periorbital creping.<\/p>\n\n\n\n High-frequency ultrasound imaging and profilometry demonstrated a statistically significant increase in dermal thickness and skin elasticity after 3 to 4 treatment sessions<\/strong>. Clinical evaluators confirmed significant smoothing of fine lines and improved tissue firmness without palpable nodules, vascular compromise, or artificial volume distortion.<\/p>\n\n\n\n Polynucleotides (PN\/PDRN) offer an effective regenerative solution for addressing structural skin atrophy. By selectively binding adenosine A2A receptors, supplying essential nucleosides via the salvage pathway, and providing viscoelastic hydration, PN\/PDRN protocols trigger natural tissue remodeling. This allows aesthetic practitioners to repair thin, damaged skin, boost native collagen density, and restore youthful tissue elasticity.<\/p>\n\n\n\n1. The Cellular Deficit: Dermal Atrophy and Matrix Collapse<\/h2>\n\n\n\n
\n
2. The Dual Bioremodeling Mechanism: Polynucleotides (PN\/PDRN)<\/h2>\n\n\n\n
A. Adenosine A2A Receptor Activation<\/h3>\n\n\n\n
\n
B. The Nucleoside “Salvage Pathway” & Isotonic Hydration<\/h3>\n\n\n\n
3. Clinical Evidence: What the Science Confirms<\/h2>\n\n\n\n
1. Selective A2A Receptor Binding and Collagen Synthesis<\/h3>\n\n\n\n
2. Clinical Improvement in Skin Elasticity and Dermal Thickness<\/h3>\n\n\n\n
4. Practice Summary<\/h2>\n\n\n\n
Study Citations & References<\/h3>\n\n\n\n
\n
Frequently Asked Questions<\/h2>\n\n\n